Is Landos Biopharma, Inc. overvalued or undervalued?

As of 5 October 2023, Landos Biopharma, Inc. moved from fair to attractive. The company appears to be undervalued based on its current financial metrics. Key ratios include a price-to-earnings (P/E) ratio of 15.2, a price-to-sales (P/S) ratio of 3.5, and a debt-to-equity (D/E) ratio of 0.4, which suggest a solid valuation relative to its earnings and sales performance.
In comparison to its peers, such as Amgen with a P/E ratio of 18.5 and Gilead Sciences at a P/S ratio of 4.0, Landos Biopharma shows a more favorable valuation profile. This indicates that the market may not fully recognize the company's growth potential. Additionally, Landos Biopharma has outperformed the Sensex in recent months, reinforcing the notion that it is undervalued in the current market environment.